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Abstract
TRIM5a (tripartite motif-containing protein-5, isoform a)–cyclophilin A fusion proteins are anti-human immu-
nodeficiency virus (HIV) restriction factors that have evolved in certain nonhuman primates over millions of
years and protect against HIV and related viruses. Restriction by TRIM5aCypA is potent and highly resistant to
viral escape by mutation and, in combination with a suitable gene delivery platform, offers the possibility of
novel therapeutic approaches against HIV. Here we report that lentiviral vector delivery of human mimics of
TRIM5a-cyclophilin A (TRIM5CypA) fusion proteins afforded robust and durable protection against HIV-1, but
resulted in downregulation of host cell antiviral responses mediated by endogenous TRIM5a. We found that
substitution of TRIM5a RING, B-box, and coiled-coil domains with similar domains from a related TRIM
protein, TRIM21, produced a novel and equally potent inhibitor of HIV-1. Both TRIM5CypA and TRIM21CypA
inhibited transduction by HIV-1-derived viral vectors and prevented propagation of replication-competent HIV-
1 in human cell lines and in primary human T cells. Restriction factor-modified T cells exhibited preferential
survival in the presence of wild-type HIV. Restriction was dependent on proteasomal degradation and was
reversed in the presence of the cyclophilin inhibitor cyclosporin. Importantly, TRIM21CypA did not disturb
endogenous TRIM5a-mediated restriction of gammaretroviral infection. Furthermore, endogenous TRIM21
antiviral activity was assessed by measuring inhibition of adenovirus–antibody complexes and was found to be
preserved in all TRIMCypA-modified groups. We conclude that lentivirus-mediated expression of the novel
chimeric restriction factor TRIM21CypA provides highly potent protection against HIV-1 without loss of normal
innate immune TRIM activity.
Introduction
Therapeutic strategies using human immunodeficiencyvirus (HIV)-1-derived lentiviral vectors to target HIV-1
infection are conceptually attractive and have been investi-
gated in phase 1 clinical trials for years, with no reports of
vector-mediated adverse effects (Levine et al., 2006). To be
efficacious, strategies must disrupt the HIV life cycle and in-
hibit the virus so that it is not prone to escape through viral
mutation. During primate evolution, in both Old and New
World monkeys, retrotransposition of the gene encoding the
HIV-binding enzyme cyclophilin A (CypA) into the TRIM5
(tripartite motif-containing protein-5) gene locus has inde-
pendently resulted in the production of novel fusion proteins
that are powerful inhibitors of primate lentiviruses (Nisole
et al., 2004; Sayah et al., 2004; Liao et al., 2007; Brennan et al.,
2008; Newman et al., 2008; Virgen et al., 2008; Wilson et al.,
2008a). TRIM5a comprises a tripartite motif consisting of
RING, B-box2, and coiled-coil (RBCC) domains. It targets the
incoming viral capsid and blocks infectivity by inhibiting re-
verse transcription through proteasome recruitment (Wu
et al., 2006) as well as by promoting innate immune signaling
through ubiquitin mediated stimulation of TAK1 phosphor-
ylation and NF-jb activation (Pertel et al., 2011). CypA is a
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peptidylprolyl isomerase that binds an exposed loop of the
HIV-1 capsid protein, an interaction that can be disrupted by
the immunosuppressive drug cyclosporin (Towers, 2007).
Oligomerization of CypA by fusion to the murine restriction
factor Fv1 creates a potent HIV-1 restriction factor, and the
restrictive potential can be increased by fusing CypA to do-
mains that, like TRIM5, can recruit the proteasome (Schaller
et al., 2007). The fusion protein TRIM5CypA, in which the
TRIM5 PRYSPRY domain has been replaced by CypA, is a
powerful inhibitor of lentiviral infection (Sayah et al., 2004;
Wilson et al., 2008b; Price et al., 2009). Importantly, human
TRIM5CypA variants have been shown to mediate robust
inhibition of HIV-1 in vitro and in human–murine chimeric
models of T cell engraftment, with no evidence of virus escape
from restrictive effects (Neagu et al., 2009). However, short
forms of TRIM5, TRIM5c and TRIM5d, that do not encode a
PRYSPRY domain can titrate natively dimeric TRIM5a pro-
teins and inhibit restriction in a dominant negative way,
thereby rescuing retroviral infectivity (Stremlau et al., 2004).
Whether the short forms are expressed naturally remains
unclear, as does the importance of this dominant negative
effect in TRIM5 biology. Data suggest that TRIM5a partici-
pates in regulation of normal innate immune signaling events
(Pertel et al., 2011), suggesting that disruption of these path-
ways by ectopic expression of TRIM5CypA could have un-
anticipated consequences. We postulated that substitution of
the TRIM5a RING, B-box2, coiled-coil, and PRYSPRY do-
mains with structurally related domains from a phylogeneti-
cally related TRIM molecule would obviate this effect. It has
been reported that heterologous RING, B-box2, and coiled-
coil domains from related TRIM proteins, including TRIM21,
can functionally substitute for rhesus TRIM5a domains (Li
et al., 2006), but studies in human proteins with fusion to
cyclophilin A have not been previously described. Here we
report that TRIM21CypA is a potent inhibitor of HIV-1 and
has favorable characteristics compared with TRIM5CypA
through preservation of endogenous antiviral activity of both
TRIM5a and TRIM21.
Materials and Methods
Lentiviral vectors
Human TRIM5aCypA and TRIM21CypA fusion cassettes
were generated by PCR amplification and cloned into a
previously described self-inactivating (SIN) HIV-1-derived
lentiviral vector encoding a spleen focus-forming virus
(SFFV) promoter and woodchuck posttranscriptional regu-
latory element (WPRE) (Demaison et al., 2002). Expression
was linked to enhanced green fluorescent protein (EGFP) by
an internal ribosomal entry sequence (IRES) as previously
described (Di et al., 2011). HIV-1 and murine leukemia viral
(MLV) vectors encoding EGFP alone or yellow fluorescent
protein (YFP) were also produced. In some experiments
modified constructs devoid of IRES-EGFP were used where
indicated.
Cells
Human embryonic kidney (HEK293T), Crandell-Reese
feline kidney (CRFK), TE671, HeLa, and GFP-encoding hu-
man osteosarcoma (GHOST) cells were maintained in Dul-
becco’s modified Eagle’s medium (Invitrogen, Paisley, UK)
supplemented with 10% fetal calf serum (Sigma, Gillingham,
UK) and penicillin–streptomycin (Invitrogen, Paisley, UK).
Jurkat T cells and SupT1 cells were maintained in RPMI with
10% fetal calf serum. Human peripheral blood mononuclear
cells (PBMCs) were isolated from healthy volunteers (with
institutional ethics committee approval) by Ficoll gradient
centrifugation and were cultured in X-VIVO 10 (Lonza,
Walkersville, MD) supplemented with human AB serum
(Lonza).
Vector production
Lentiviral vector stocks were produced by transient
transfection of subconfluent HEK293T cells with vector
plasmid, vesicular stomatitis virus (VSV) envelope plasmid
(pMDG), and gag/pol packaging plasmid (pCMVD8.74) as
previously described (Qasim et al., 2007). Viral supernatant
was harvested 48 and 72 hr later, filtered (pore size,
0.22 lm), and concentrated by ultracentrifugation before
cryopreservation.
B- and N-tropic MLV retroviral stocks expressing YFP
were produced by transient transfection of HEK293T cells
with pCNCY, pMDG2, and pCIG3 (B- or N-tropic), using
Lipofectamine 2000 (Invitrogen, Paisley, UK). TRIMCypA
gammaretroviral vector stocks was produced by transient
transfection of HEK293T cells with pEXN-TRIMCyp, pMDG,
and Moloney murine leukemia viral (MoMLV) gag/pol
packaging plasmid (pCMVi), using FuGENE 6 (Roche, Bur-
gess Hill, UK). Retrovirus-containing supernatant was har-
vested 48 and 72 hr later before filtration (pore size, 0.45 lm)
and cryopreservation. Viral titers were quantified by flow
cytometry and/or quantitative PCR as previously described
(Vink et al., 2009).
HIV-1 viral stocks
NL4-3 encoding Ba-L envelope and HIV-1 R9 plasmids
(Centre for AIDS Reagents, National Institute for Biological
Standards and Control [NIBSC], Potters Bar, UK) were
transfected into HEK293T cells, using FuGENE 6 (Roche),
and viral supernatant was harvested 48 and 72 later, filtered
(pore size, 0.45 lm), and cryopreserved. Viral titer was
quantified by p24 ELISA as described below.
Quantitative PCR
HEK293T cells (1· 105) were exposed to serial dilutions of
lentiviral vector, and 72 hr later the genomic DNA was ex-
tracted. A primer–probe set targeting the WPRE sequence
was used to detect integrated lentiviral vector copies, and the
data were normalized against b-actin gene copy and titer
calculated as previously described (Vink et al., 2009).
ELISA
p24 levels in HIV-1 viral stocks were quantified by p24
ELISA (ZeptoMetrix, Buffalo, NY) according to manufac-
turer’s guidelines. Absorbance was read with a FLUOstar
OPTIMA (BMG Labtech, Offenburg, Germany).
Flow cytometry
GFP and YFP were measured by flow cytometry, using a
BD LSR II analyzer (BD Biosciences, San Jose, CA) and
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FACSDiva software. Cells were sorted on a MoFlo XDP
sorter (Beckman Coulter, Miami, FL). A set of dichroic mir-
rors and optical filters was used to separate GFP and YFP on
the LSR II analyzer. A 525LP dichroic mirror was used
to separate GFP and YFP signals. Cells were washed in
phosphate-buffered saline (PBS) before fixation in 4% para-
formaldehyde. Viable cells negative for LIVE/DEAD stain
(Invitrogen, Paisley, UK) were back-gated on a forward/side
scatter plot to confirm that they were included in the original
viability gate.
Western blot
Transduced CRFK cells were suspended in lysis buffer
(60 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate [SDS],
10% glycerol, 5% 2-mercaptoethanol, 0.01% bromophenol
blue) and boiled at 100C for 10 min. Protein was resolved on
NuPAGE Novex 4–12% Bis-Tris gels with 2-(N-morpholino)
ethanesulfonic acid (MES) buffer (Invitrogen, Carlsbad, CA)
and transferred onto polyvinylidene difluoride (PVDF)
membrane. Blots were probed with anti-cyclophilin antibody
(SA296; Enzo Life Sciences, Exeter, UK). Anti-rabbit horse-
radish peroxidase-conjugated secondary antibody (NA934;
GE Healthcare, Buckinghamshire, UK) and a Pierce en-
hanced chemiluminescence (ECL) detection kit (Thermo
Scientific, Rockford, IL) were used to visualize bands.
Restriction assays
CRFK cells were transduced with lentiviral vector encod-
ing TRIM5CypA or TRIM21CypA. Transduction was con-
firmed by flow cytometry for EGFP before challenge with
HIV-YFP vector at a multiplicity of infection (MOI) of 3 in
the presence or absence of 5lM cyclosporin (Sandoz Phar-
maceuticals, Camberley, UK), a competitive inhibitor of cy-
clophilin A binding. Flow cytometry was used to quantify
HIV-YFP infection 72 hr later. Culture in the presence of the
proteasome inhibitor MG132 was used to determine whether
restriction by TRIM21CypA was mediated by proteasomal
degradation as previously reported for TRIM5CypA. In these
experiments, viral DNA was assessed by quantitative PCR in
order to provide a measure of HIV genomes, which had
undergone reverse transcription. Human PBMCs were acti-
vated with anti-CD3/anti-CD28 beads at a 1:1 ratio (In-
vitrogen Dynal, Oslo, Norway) in the presence of interleukin
(IL)-2 (Proleukin, 100 U/ml; Chiron/Novartis Diagnostics,
Emeryville, CA) for 48 hr before lentiviral transduction as
previously described (Qasim et al., 2007). HIV-YFP challenge
at an MOI of 35 after 72 hr was assessed by flow cytometry to
determine levels of HIV restriction. In experiments testing
challenge by replication-competent HIV-1, GHOST cells
were transduced with TRIMCyp vectors and purified by
flow cytometric sorting for GFP and CCR5 expression. Sor-
ted cells were seeded at 5 · 104 in triplicate and subjected to a
single round of infection with 2 ng of HIV-1 NL4-3 encoding
a Ba-L envelope gene (NL4-3 Ba-L) and cultured over 28
days. Culture medium was harvested at 1-week intervals
and p24 levels were measured by ELISA. For primary cell
experiments, transduced human T cells were enriched by
flow cytometric cell sorting, gating on CD4 +/GFP double-
positive cells after lentiviral transduction and compared with
nontransduced enriched CD4+ T cells. Purified cells were
seeded in triplicate in 96-well U-bottom plates and chal-
lenged with NL4-3 Ba-L, and viral propagation was assessed
by measurement of p24 in the culture supernatant by ELISA
5 days later.
Endogenous TRIM response assays
Endogenous TRIM5a activity was assessed in TE671 cells,
transduced with lentiviral TRIMCypA vectors, and cultured
in the presence of 1000 U of interferon (IFN)-b. Cells were
challenged with either HIV-YFP or with B- or N-MLV-YFP
vectors and then assessed for YFP expression by flow cy-
tometry, gating on the EGFP-positive fraction. Endogenous
TRIM21 activity was assessed by determination of adenovi-
rus-GFP infection inhibition as described (Mallery et al.,
2010). Briefly, TRIM21 restricts adenoviral infection of HeLa
cells after incubation with adenovirus-specific serum, and
this effect is augmented in the presence of IFN-a. HeLa cells
were transduced to express TRIMCyp (using vectors devoid
of EGFP) and were exposed to adenovirus-GFP opsonized
with a monoclonal antibody against adenovirus (9C12; De-
velopmental Studies Hybridoma Bank, University of Iowa,
Iowa City, IA) and examined by flow cytometry for EGFP
expression.
Statistics
Where shown, error bars represent the standard error of
the mean of the replicates indicated, and differences were
found to be significant by Student t test at p< 0.05.
Results
Lentivirus-mediated TRIMCypA restriction of HIV
A fragment encoding the first 284 amino acids of TRIM21,
encoding its RBCC motif, and a fragment encoding the first
306 amino acids of the TRIM5a RBCC motif were fused in-
frame to a human CypA cDNA and cloned into an SIN HIV-
1 construct encoding a strong retroviral promoter (from
SFFV) and linked to an EGFP reporter gene (Fig. 1A) (Qasim
et al., 2007; Di et al., 2011). To test for restriction activity
TRIMCypA/EGFP was expressed in permissive CRFK cells.
These cells were then challenged with a VSV-G-pseudotyped
replication-defective HIV-1-based vector encoding YFP.
When TRIMCyp expression restricted infection, cells coex-
pressing EGFP were protected from infection by incoming
HIV-YFP. In the absence of restriction both the green and
nongreen populations became equally infected by HIV-YFP.
These experiments were performed in the presence or ab-
sence of cyclosporin, a reversible inhibitor of CypA binding
and thus an inhibitor of TRIMCyp restriction. In cell lines
transduced with control vectors expressing EGFP alone, high
levels of YFP and EGFP coexpression were seen after HIV-1-
YFP infection, as expected. In contrast, when cells expressed
EGFP in combination with TRIM5CypA or TRIM21CypA,
the modified cells were protected from infection and YFP
coexpression was not observed after HIV-1-YFP infection
(Fig. 1B). Both TRIM5CypA and TRIM21CypA expression
protected the green cells from infection by HIV-1 encoding
YFP. In the presence of cyclosporin, the restrictive effects of
both TRIM5CypA and TRIM21CypA were abrogated, al-
lowing the expression of YFP in the GFP-positive cells. In
repeat experiments, 100-fold HIV-1 restriction was
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consistently afforded by both TRIM5CypA and TRIM21Cy-
pA expression.
It is possible to saturate restriction effects mediated by
TRIM5CypA, and similar effects have been reported for
TRIM5a (Towers et al., 2002). We compared restriction me-
diated by TRIM5CypA and TRIM21CypA in transduced
CRFK cells exposed to HIV-YFP up to an MOI of 1000. Flow
cytometry for YFP expression was undertaken 72 hr after
challenge with HIV-1-YFP (Fig. 1C). Control populations
(nontransduced or expressing GFP alone) were all trans-
duced by HIV-YFP at an MOI of 10. In contrast, both
TRIM5CypA- and TRIM21CypA-modified cells exhibited
similar saturation effects, and required exposure to an MOI of
1000 to achieve complete transduction, providing further ev-
idence for a similar mechanism of action.
Western blot analysis confirmed expression of the
appropriate-sized fusion proteins, with TRIM5CypA at
53 kDa, TRIM21CypA at 51 kDa, and endogenous cyclophi-
lin A at 18 kDa (Fig. 1D). Retroviral restriction mediated by
TRIM5CypA has previously been shown to involve the
FIG. 1. Lentivirus-mediated expression of TRIMCypA restriction factors. (A) Schematic representation of native TRIM5a
showing RING, B-box2, coiled-coil, and B30.2 (PRYSPRY) domains. Substitution of the B30.2 domain with human cyclophilin
A (CypA) produced TRIM5CypA. An analogous construct was derived from TRIM21 to produce TRIM21CypA. The
transgene cassettes were cloned into a self-inactivating lentiviral vector under the control of the spleen focus-forming virus
long terminal repeat (SFFV LTR) and linked to expression of EGFP by an internal ribosomal entry sequence (IRES). (B)
Challenge of transduced CRFK cells with HIV-YFP in the presence or absence of cyclosporin (Cs). Flow cytometry of cells
revealed high levels of YFP and EGFP coexpression in cells transduced with control vectors expressing EGFP alone, but cells
transduced to express TRIM5CypA or TRIM21CypA, did not coexpress YFP (top), indicating highly specific restriction. Cs
inhibited these restrictive effects (bottom). (C) Transduced CRFK cells expressing GFP alone or in combination with
TRIM5CypA and TRIM21CypA were exposed to increasing MOIs of HIV-YFP. Flow cytometry for YFP expression was
undertaken 72 hr later and showed efficient transduction of control populations at MOIs less than 10. Both TRIM5CypA and
TRIM21CypA exhibited similar saturation effects, and required exposure to an MOI of 1000 to achieve complete transduction.
(D) Western blotting of lentivirally transduced CRFK cells using anti-CypA antibody detected the presence of TRIMCyp
species (TRIM5CypA 53kDa and TRIM21CypA 51kDa) in transduced populations (lanes 2 and 3) as well as native cyclophilin
A (18 kDa) in control vector transduced cells (lane 1) and b-actin (bottom). (E) TRIM21CypA restriction of HIV reverse
transcription was rescued by proteasomal inhibition by MG132, manifested as increased copies of GFP DNA. Rescue at this
level was only partial, as GFP expression was still reduced compared with control (vector only) modified cells. Restriction
was fully abrogated by treatment with Cs. (F) Flow cytometry showing inhibition of HIV-YFP infectivity in primary T cells
transduced to express TRIM5CypA or TRIM21CypA, manifested as an absence of EGFP–YFP coexpression. NT, non-
transduced control cells.
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proteasome (Anderson et al., 2006). Accordingly, the pro-
teasome inhibitor MG132 inhibited restriction of viral DNA
synthesis mediated by TRIM21CypA, indicating that
TRIM21CypA is likely to restrict infection in a mechanisti-
cally similar way to TRIM5CypA (Fig. 1E).
We next assessed the ability of TRIM21CypA and
TRIM5CypA proteins to restrict HIV-1 infection in primary
human T cells. TRIMCypA-expressing cells were again
identified by coexpression of EGFP, and these cells clearly
excluded YFP, whereas control cells exhibited good levels of
YFP expression as expected (Fig. 1F). Our results demon-
strate that lentiviral vectors encoding either TRIM21CypA or
TRIM5CypA can transduce human primary T cells and can
restrict subsequent infection with HIV-1.
TRIMCypA proteins inhibit HIV replication
and confer a survival advantage
The HIV-1-permissive GHOST cell line was transduced
with lentiviral constructs expressing TRIMCypA genes, and
FIG. 1. (Continued).
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FIG. 2. (A) TRIM5CypA and TRIM21CyA inhibit HIV replication. GHOST cells transduced and enriched for EGFP/
TRIMCypA expression were infected with HIV-1 NL4-3 (Ba-L Env) and virus propagation was quantified by ELISA for p24
after 7 days. TRIM5CypA and TRIM21CypA groups had low levels of detectable p24 whereas in control cultures, HIV-1 had
propagated as anticipated. NT, nontransduced control cells (n= 3). (B) In cultures tracked for 28 days, we found that GHOST
cells fully modified to express TRIM5CypA or TRIM12CypA did not support HIV propagation, and p24 levels were barely
detectable by ELISA in these cultures. In contrast, nontransduced control populations had high p24 levels within 7 days of
exposure to HIV, and cultures did not survive beyond this period, precluding further assessments (n = 3). (C) Transduced
primary T cells were enriched on the basis of CD4 and GFP coexpression and seeded in triplicate before challenge with HIV.
Nontransduced T cells, or cells modified to express GFP alone, supported HIV replication and p24 was detectable within 5
days. In contrast, p24 levels in supernatant collected from TRIM5CypA- or TRIM21CypA-modified T cells were barely
detectable, with no significant difference between TRIMCypA-modified populations (n= 6, from two independent experi-
ments). (D) SupT1 cells transduced to express TRIM5CypA or TRIM21CypA (linked to EGFP) were exposed to replication-
competent HIV-1 in culture. Over a period of 14–28 days cells expressing HIV restriction factors increased in frequency,
indicating preferential survival in the presence of replicating virus. (E) Survival advantage of TRIMCypA-modified popu-
lations was investigated in cultures in which approximately 20% of lentivirus-transduced cells were expressing GFP. Jurkat T
cell viability was monitored by serial flow cytometry (with viability gating validated by LIVE/DEAD dye staining) and was
found to be markedly reduced within 10 days of culture with HIV-1-nontransduced (NT) and GFP-transduced control
populations. In cultures of TRIM5CypA- and TRIM21CypA-modified cells, the lowest viability mirrored the 20% proportion
of cells expressing restriction factor and thus protected against HIV, and this rapidly improved over a further 7- to 14-day
period, suggesting a strong survival advantage in the presence of replicating HIV.
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the modified cells were enriched to high purity by flow cy-
tometric cell sorting. Cells were then infected with a high
multiplicity of replication-competent HIV-1 NL4-3 (Ba-L)
and cultured for 28 days (Fig. 2A and B). Quantification of
HIV-1 p24 in the culture supernatant by ELISA found un-
detectable levels of HIV-1 in either the TRIM5CypA- or
TRIM21CypA-expressing cells for up to 4 weeks. In contrast,
control cultures supported HIV-1 propagation as anticipated,
with high levels of p24 detected by 7 days, and cell death
thereafter. These data indicate robust protection over pro-
longed culture times and suggest that in cell cultures highly
purified for TRIMCyp expression, HIV-1 is unable to escape
restriction and thus the life cycle of the virus effectively
terminates. We also investigated the ability of TRIMCypA to
prevent HIV-1 infection and propagation in primary human
T cells. Human PBMCs were activated for 48 hr with anti-
CD3/anti-CD28 beads and transduced with lentiviral vectors
expressing either GFP alone or in combination with TRIM-
CypA. Five days later, highly purified populations of CD4 +/
GFP + T cells were challenged with HIV-1 NL4-3 and cul-
tured for a further 5 days before ELISA-based quantification
of p24 in the culture supernatant. Whereas p24 was detected
in nontransduced cells as well as cells expressing EGFP
alone, p24 levels in supernatant collected from TRIMCypA-
modified cells were barely detectable. This indicates that
both TRIM5CypA and TRIM21CypA had restricted replica-
tion-competent HIV in primary T cells (Fig. 2C).
We next prepared populations of SupT1 cells coexpressing
EGFP and TRIMCypA fusion proteins, with about 10% of the
cells expressing the restriction factor. We then infected these
cultures with replication-competent HIV-1 clone R9. Flow
cytometry quantified EGFP expression and cell viability over
a period of 4 weeks, and revealed an increasing proportion of
TRIMCypA-expressing cells, indicating a survival advantage
in the presence of replication-competent HIV-1 (Fig. 2D). The
survival advantage conferred by TRIM5CypA and TRIM21-
CypA was further demonstrated in Jurkat T cells by mea-
suring viability of transduced populations over time.
Whereas viability of control populations exposed to HIV
deteriorated over 7–14 days, cultures in which about 20% of
cells were modified to express TRIMCypA proteins recov-
ered viability after an initial decline to about 20%, again
supporting the notion of a powerful survival advantage for
cells expression TRIMCyp chimeras (Fig. 2E).
TRIM5CypA but not TRIM21CypA disrupts
endogenous TRIM5 activity
For therapeutic purposes it would be advantageous to
select chimeric TRIMCypA restriction factors that do not
disturb the endogenous innate functions of the parental
TRIM proteins. The ability of TRIM5CypA-expressing cells
to restrict gammaretrovirus through endogenous TRIM5a
was therefore investigated. We used TRIM5a-sensitive MLV-
N and TRIM5a-insensitive MLV-B and HIV-1 (all expressing
YFP) as controls. As expected, unmodified cells strongly re-
stricted MLV-N but not MLV-B, or HIV-1, and this effect was
augmented in the presence of IFN-b, which is known to
stimulate TRIM5a expression (Fig. 3). However, cells ex-
pressing TRIM5CypA were unable to restrict MLV-N, even
in the presence of IFN-b. This observation confirms that
TRIM5CypA chimeras have dominant negative activity
FIG. 3. TRIM5CypA but not TRIM21CypA inhibits endog-
enous TRIM5 function. (A) Loss of TRIM5-mediated restriction
of the gammaretrovirus N-MLV was seen in cells modified to
express TRIM5CypA, and this effect could not be rescued with
interferon (IFN). TRIM21CypA-transduced cells retain their
ability to restrict N-MLV-YFP, and as in the control groups,
IFN-b augmented this effect, reducing YFP to background
levels. (B) B-MLV was not restricted by either endogenous
TRIM5a or the TRIMCyp proteins whereas (C) HIV was re-
stricted by both TRIM5CypA and TRIM21CypA (n=3).
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against endogenous TRIM5 and even treatment with IFN-b,
which increases production of endogenous TRIM5a, cannot
overcome the dominant negative effect. In sharp contrast,
TRIM21CypA expression did not inhibit endogenous TRI-
M5a activity in these experiments, and N-MLV-YFP infec-
tivity was reduced to below the limits of detection (Fig. 3A).
As predicted, both TRIM5CypA and TRIM21CypA did not
restrict B-MLV, even in the presence of IFN (Fig. 3B), but did
notably inhibit HIV-1 (Fig. 3C).
TRIM21 function is preserved
in TRIMCypA-modified cells
TRIM21 binds intracellular antibody via its PRYSPRY do-
main. This activity is conserved across mammals, and provides
a novel interface between humoral and innate immunity
(Mallery et al., 2010). Transduction of HeLa cells by an ade-
noviral vector expressing EGFP (ADV-GFP) can be prevented
when the virus is preincubated with monoclonal neutralizing
antibody, and we first confirmed that this effect is depen-
dent on endogenous TRIM21 activity. Briefly, cells in which
TRIM21 was knocked down by short hairpin RNA interference
(shRNAi) became susceptible to ADV-GFP, whereas control
populations resisted infection in a manner dependent on the
concentration of neutralizing antibody (Fig. 4A and B). We
next undertook similar experiments in cells transduced with
TRIM5CypA or TRIM21CypA, and found that these popula-
tions retained their ability to block ADV-GFP infection, both in
the presence or absence of IFN-a (Fig. 4C), indicating that there
was no disruption of endogenous TRIM21 antiviral function.
Discussion
Highly active antiretroviral therapy (HAART) against HIV
is effective in controlling HIV-1 replication, and reduces
morbidity and mortality (Palella et al., 1998), but there are
widespread issues relating to cost, compliance, and side ef-
fects. Alternative therapies based on the use of gammare-
troviral, lentiviral, and adenoviral vectors are in early-phase
clinical studies, testing a variety of anti-HIV strategies in-
cluding disruption of CCR5 (Ledford, 2011), expression of
anti-Env sequences (Levine et al., 2006), anti-HIV ribozymes
(Mitsuyasu et al., 2009), fusion inhibitors (van Lunzen et al.,
2007), and other approaches (Rossi et al., 2007). Here we have
investigated the feasibility of developing a gene therapy strat-
egy against HIV-1 that is based on lentivirus-mediated ex-
pression of human TRIM5CypA, reasoning that similar
molecules appear to have evolved for this purpose in certain
nonhuman primates. In human cells, Neagu and colleagues
(2009) found that human mimics of simian TRIM5CypA po-
tently inhibited HIV-1 and they reported durable, escape-
resistant restriction in vitro and in vivo in a human–murine
chimeric animal model. This strongly suggests that any muta-
tion of the HIV-1 capsid sequence that leads to viral escape
from TRIM5CypA-mediated restriction would have detrimen-
tal consequences for viral fitness. It has been shown that HIV-1
mutants that do not recruit cyclophilins integrate into different
regions of chromatin and replicate poorly in cell lines and
primary cells, in part due to an inability to interact with the
nuclear pore cyclophilin Nup358 (Schaller et al., 2011). For this
reason we believe that the emergence of TRIMCypA-resistant
mutants is unlikely to occur and further that cyclophilin-
binding mutants are likely to have severe replication defects.
FIG. 4. Endogenous TRIM21 restricts adenovirus in the
presence of neutralizing antibody, and functions in TRIM5-
CypA- or TRIM21CypA-expressing cells. (A) HeLa cells sta-
bly knocked down for TRIM21 (T21 kd) or control cells
expressing nontargeting shRNA (Control kd) were infected
with adenovirus-GFP incubated with a neutralizing (Neut
mAb) or isotype-matched control (Control mAb) antibody.
The control shRNA-expressing cells efficiently neutralized
adenovirus infection when neutralizing antibody was pres-
ent. In contrast, HeLa cells depleted for TRIM21 were less
efficient in neutralizing adenovirus infection in the presence
of neutralizing antibody. (B) Confirmation that interferon-a
induced TRIM21 expression, and this could be depleted by
shRNAi targeting TRIM21 but not by control shRNAi. (C)
After lentiviral transduction, TRIM5CypA- and TRIM21Cy-
pA-modified cells retained their ability to restrict adenovirus
treated with neutralizing antibody, in the presence or absence
of interferon-a, indicating intact endogenous TRIM21 activity
in all populations. NT, nontransduced control cells (n= 3).
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We have independently confirmed the potency of human
TRIM5CypA against HIV but also found that domains from
a related TRIM protein, TRIM21, can substitute for TRIM5a
in the fusion construct. Both TRIM5CypA and TRIM21CypA
mediated equally potent anti-HIV effects in human cell lines
and in primary human T cells. However, TRIM21CypA had
the advantage of not disrupting the known antiviral activi-
ties of endogenous TRIM5a or TRIM21. Overexpression of
TRIM5CypA compromised endogenous TRIM5a function,
probably through direct interaction between the two TRIM
moieties. Although data suggest that simian TRIM5CypA
activates the TAK1 and NF-jB pathways (Pertel et al., 2011)
and in turn may mediate inhibitory feedback on TRIM5a
transcription, TRIM5a mRNA levels in transduced cells were
comparable to those in nonmodified populations. Notably,
cells expressing TRIM21CypA not only retain IFN-mediated
endogenous TRIM5a responses but also exhibited intact
TRIM21 function. Until more recently, little was known
about the antiviral activity of TRIM21, and here we have
used an assay (Mallery et al., 2010) to show that the molecule
mediates restriction of antibody–virion complexes and inhi-
bition of adenovirus-mediated GFP expression. This effect is
thought to be mediated by the PRYSPRY domain of the
TRIM21 molecule through a stoichiometric complex with one
antibody molecule. We speculate that an excess of TRIM21-
CypA (which is devoid of the PRYSPRY domain) does not
interfere with the endogenous antiviral pathway of TRIM21.
Thus as a therapeutic antiviral approach, TRIM21CypA
vectors could have important advantages over TRIM5CypA-
based strategies. One potential problem with a TRIM21-
based expression strategy is the connection between TRIM21
and the rare chronic autoimmune diseases systemic lupus
erythematosus (SLE) and Sjo¨gren syndrome. TRIM21 is the
target of autoantibodies (anti-Ro52) present in some of these
individuals, although the role of these antibodies in the
disease remains unclear. Anti-Ro52 antibodies are polyclonal
but the most immunogenic epitopes implicated in autoim-
mune disease reside within the B30.2 domain and carboxy
terminus (Burbelo et al., 2010). Importantly, these regions are
not present in the TRIM21CypA restriction factor described
here, reducing the risk of autoimmune rejection of TRIM21-
CypA-modified cells by typical anti-Ro52 antibodies.
In the first instance, the safety and efficacy of anti-HIV
gene therapy approaches using TRIM21CypA will be in-
vestigated by ex vivo modification and reinfusion of T cells or
T cell precursor stem cells. If such modification confers a
survival advantage in vivo through sustained protection
against HIV, a relatively small number of engineered cells
could expand and reconstitute cellular immunity within a
period of a few months, offering a valuable alternative to
conventional antiretroviral drug therapy.
Acknowledgments
This work was supported by a Jules Thorn Trust award
(E.C.), Wellcome Trust fellowships (A.T. and G.J.T.), Leukaemia
Research and Great Ormond Street Hospital Children’s Charity
funding (W.Q.), and R&D funding from the U.K. Department of
Health, the UCL Medical Research Council Centre for Medical
Molecular Virology, and grants from the Medical Research
Council and the National Institutes of Health Research via
UCL/UCLH Comprehensive Biomedical Research Centres.
Author Disclosure Statement
The authors declare that there are no conflicts of interest.
References
Anderson, J.L., Campbell, E.M., Wu, X., et al. (2006). Proteasome
inhibition reveals that a functional preintegration complex
intermediate can be generated during restriction by diverse
TRIM5 proteins. J. Virol. 80, 9754–9760.
Brennan, G., Kozyrev, Y., and Hu, S.L. (2008). TRIMCyp ex-
pression in Old World primates Macaca nemestrina and Macaca
fascicularis. Proc. Natl. Acad. Sci. U.S.A. 105, 3569–3574.
Burbelo, P.D., Ching, K.H., Han, B.L., et al. (2010). Extraordinary
antigenicity of the human Ro52 autoantigen. Am. J. Transl.
Res. 2, 145–155.
Demaison, C., Parsley, K., Brouns, G., et al. (2002). High-level
transduction and gene expression in hematopoietic re-
populating cells using a human imunodeficiency virus type 1-
based lentiviral vector containing an internal spleen focus
forming virus promoter. Hum. Gene Ther. 13, 803–813.
Di, W.L., Larcher, F., Semenova, E., et al. (2011). Ex-vivo gene
therapy restores LEKTI activity and corrects the architecture of
Netherton syndrome-derived skin grafts. Mol. Ther. 19, 408–416.
Ledford, H. (2011). Targeted gene editing enters clinic. Nature
471, 16.
Levine, B.L., Humeau, L.M., Boyer, J., et al. (2006). Gene transfer
in humans using a conditionally replicating lentiviral vector.
Proc. Natl. Acad. Sci. U.S.A. 103, 17372–17377.
Li, X., Li, Y., Stremlau, M., et al. (2006). Functional replacement
of the RING, B-box 2, and coiled-coil domains of tripartite
motif 5a (TRIM5a) by heterologous TRIM domains. J. Virol.
80, 6198–6206.
Liao, C.H., Kuang, Y.Q., Liu, H.L., et al. (2007). A novel fusion
gene, TRIM5-Cyclophilin A in the pig-tailed macaque deter-
mines its susceptibility to HIV-1 infection. AIDS 21(Suppl. 8),
S19–S26.
Mallery, D.L., McEwan, W.A., Bidgood, S.R., et al. (2010). Anti-
bodies mediate intracellular immunity through tripartite
motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. U.S.A.
107, 19985–19990.
Mitsuyasu, R.T., Merigan, T.C., Carr, A., et al. (2009). Phase 2
gene therapy trial of an anti-HIV ribozyme in autologous
CD34 + cells. Nat. Med. 15, 285–292.
Neagu, M.R., Ziegler, P., Pertel, T., et al. (2009). Potent inhibition
of HIV-1 by TRIM5-cyclophilin fusion proteins engineered
from human components. J. Clin. Invest. 119, 3035–3047.
Newman, R.M., Hall, L., Kirmaier, A., et al. (2008). Evolution of a
TRIM5-CypA splice isoform in Old World monkeys. PLoS
Pathogens 4, e1000003.
Nisole, S., Lynch, C., Stoye, J.P., and Yap, M.W. (2004). A Trim5-
cyclophilin A fusion protein found in owl monkey kidney cells
can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101, 13324–13328.
Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., et al.; HIV
Outpatient Study Investigators. (1998). Declining morbidity
and mortality among patients with advanced human immu-
nodeficiency virus infection. N. Engl. J. Med. 338, 853–860.
Pertel, T., Hausmann, S., Morger, D., et al. (2011). TRIM5 is an
innate immune sensor for the retrovirus capsid lattice. Nature
472, 361–365.
Price, A.J., Marzetta, F., Lammers, M., et al. (2009). Active site
remodeling switches HIV specificity of antiretroviral TRIM-
Cyp. Nat. Struct. Mol. Biol. 16, 1036–1042.
Qasim, W., Mackey, T., Sinclair, J., et al. (2007). Lentiviral vectors
for T-cell suicide gene therapy: Preservation of T-cell effector
1184 CHAN ET AL.
function after cytokine-mediated transduction. Mol. Ther. 15,
355–360.
Rossi, J.J., June, C.H., and Kohn, D.B. (2007). Genetic therapies
against HIV. Nat. Biotechnol. 25, 1444–1454.
Sayah, D.M., Sokolskaja, E., Berthoux, L., and Luban, J. (2004).
Cyclophilin A retrotransposition into TRIM5 explains owl
monkey resistance to HIV-1. Nature 430, 569–573.
Schaller, T., Ylinen, L.M., Webb, B.L., et al. (2007). Fusion of
cyclophilin A to Fv1 enables cyclosporine-sensitive restriction
of human and feline immunodeficiency viruses. J. Virol. 81,
10055–10063.
Schaller, T., Ocwieja, K.E., Rasaiyaah, J., et al. (2011). HIV-1
capsid–cyclophilin interactions determine nuclear import
pathway, integration targeting and replication efficiency.
PLoS Pathogens 7, e1002439.
Stremlau, M., Owens, C.M., Perron, M.J., et al. (2004). The cy-
toplasmic body component TRIM5a restricts HIV-1 infection
in Old World monkeys. Nature 427, 848–853.
Towers, G.J. (2007). The control of viral infection by tripartite
motif proteins and cyclophilin A. Retrovirology 4, 40.
Towers, G., Collins, M., Takeuchi, Y. (2002) Abrogation of Ref1
retrovirus restriction in human cells. J Virol. 76, 2548–2550.
van Lunzen, J., Glaunsinger, T., Stahmer, I., et al. (2007). Transfer
of autologous gene-modified T cells in HIV-infected patients
with advanced immunodeficiency and drug-resistant virus.
Mol. Ther. 15, 1024–1033.
Vink, C.A., Gaspar, H.B., Gabriel, R., et al. (2009). Sleeping
beauty transposition from nonintegrating lentivirus. Mol.
Ther. 17, 1197–1204.
Virgen, C.A., Kratovac, Z., Bieniasz, P.D., and Hatziioannou, T.
(2008). Independent genesis of chimeric TRIM5-cyclophilin
proteins in two primate species. Proc. Natl. Acad. Sci. U.S.A.
105, 3563–3568.
Wilson, S.J., Webb, B.L., Ylinen, L.M., et al. (2008a). Independent
evolution of an antiviral TRIMCyp in rhesus macaques. Proc.
Natl. Acad. Sci. U.S.A. 105, 3557–3562.
Wilson, S.J., Webb, B.L., Ylinen, L.M., et al. (2008b). Independent
evolution of an antiviral TRIMCyp in rhesus macaques. Proc.
Natl. Acad. Sci. U.S.A. 105, 3557–3562.
Wu, X., Anderson, J.L., Campbell, E.M., et al. (2006). Proteasome
inhibitors uncouple rhesus TRIM5a restriction of HIV-1 re-
verse transcription and infection. Proc. Natl. Acad. Sci. U.S.A.
103, 7465–7470.
Address correspondence to:
Dr. Waseem Qasim
UCL Institute of Child Health
30 Guilford Street
London, WC1N 1EH
United Kingdom
E-mail: W.Qasim@ich.ucl.ac.uk
Received for publication April 17, 2012;
accepted after revision August 9, 2012.
Published online: August 21, 2012.
POTENT HIV RESTRICTION FACTOR TRIM21CYPA 1185
